H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod

Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) is among the most promising stocks.

On February 23, 2026, H.C. Wainwright accrued the terms people for ARMP from $9.00 to $15.00 and kept a Buy standing connected the shares. The modification comes aft the FDA designated AP-SA02 arsenic a Qualified Infectious Disease Product, providing other regulatory enactment arsenic the concern gets acceptable for its Phase 3 superiority research, which is acceptable for the 2nd fractional of 2026.

Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) declared connected February 23 that its intravenous Staphylococcus aureus multi-phage candidate, AP-SA02, has been fixed Qualified Infectious Disease Product (QIDP) classification by the U.S. FDA. Its usage arsenic an adjuvant attraction for analyzable bacteremia brought connected by some methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) S. aureus is covered by the designation. In the 2nd fractional of 2026, the institution plans to spot AP-SA02 into a Phase 3 superiority proceedings for analyzable bloodstream infections caused by S. aureus.

Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) is simply a clinical-stage biotech institution processing precision bacteriophage-based therapies to dainty antibiotic-resistant and hard-to-treat bacterial infections, advancing a pipeline of pathogen-specific phage candidates from find done objective trials.

While we admit the imaginable of ARMP arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 14 Best GARP Stocks to Buy According to Analysts and 14 Best Affordable Dividend Stocks to Buy According to Analysts.

Disclosure: None. Follow Insider Monkey connected Google News.